Tags

Type your tag names separated by a space and hit enter

Antiviral activities of type I interferons to SARS-CoV-2 infection.
Antiviral Res. 2020 07; 179:104811.AR

Abstract

There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Mantlo E
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Bukreyeva N
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Maruyama J
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Paessler S
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Huang C
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: chhuang@utmb.edu.

MeSH

AnimalsAntiviral AgentsBetacoronavirusCOVID-19Chlorocebus aethiopsCoronavirus InfectionsHumansImmunity, InnateInterferon Type IInterferon-alphaInterferon-betaPandemicsPneumonia, ViralRecombinant ProteinsSARS-CoV-2Severe Acute Respiratory SyndromeVero CellsViral LoadVirus Replication

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32360182

Clinical Trial Links

Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

Citation

Mantlo, Emily, et al. "Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection." Antiviral Research, vol. 179, 2020, p. 104811.
Mantlo E, Bukreyeva N, Maruyama J, et al. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020). Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Research, 179, 104811. https://doi.org/10.1016/j.antiviral.2020.104811
Mantlo E, et al. Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection. Antiviral Res. 2020;179:104811. PubMed PMID: 32360182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiviral activities of type I interferons to SARS-CoV-2 infection. AU - Mantlo,Emily, AU - Bukreyeva,Natalya, AU - Maruyama,Junki, AU - Paessler,Slobodan, AU - Huang,Cheng, Y1 - 2020/04/29/ PY - 2020/04/05/received PY - 2020/04/19/revised PY - 2020/04/25/accepted PY - 2020/5/4/pubmed PY - 2020/6/24/medline PY - 2020/5/4/entrez KW - Antiviral therapy KW - COVID-19 KW - Innate immune KW - Interferon KW - SARS-CoV-2 SP - 104811 EP - 104811 JF - Antiviral research JO - Antiviral Res VL - 179 N2 - There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/32360182/Antiviral_activities_of_type_I_interferons_to_SARS_CoV_2_infection_ DB - PRIME DP - Unbound Medicine ER -